Study Comparing Olanzapine With Haloperidol for the Relief of Nausea and Vomiting in Patients With Advanced Cancer

Last updated: January 18, 2012
Sponsor: Alberta Health Services
Overall Status: Terminated

Phase

3

Condition

Colic

Lactose Intolerance

Stomach Discomfort

Treatment

N/A

Clinical Study ID

NCT00124930
18731
ISRCTN58624349
MCT 71119
  • Ages > 18
  • All Genders

Study Summary

The purpose of this study is to compare the efficacy and safety of Haldol (haloperidol) and olanzapine in the control of chronic nausea with advanced cancer patients who have failed first line antiemetic therapy.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • >18 years of age

  • Significant nausea/vomiting

  • Failed maxeran and domperidone

  • Underlying treatment of causes has failed

  • Adequate cognitive function

  • Communicates well

Exclusion

Exclusion Criteria:

  • Partial/complete bowel obstruction

  • Currently taking Haldol or olanzapine

  • Has drug induced extrapyramidal symptoms

  • Parkinson's disease

  • Undergoing chemotherapy or radiotherapy (RT) to brain, abdomen, stomach or esophagus

Study Design

Total Participants: 80
Study Start date:
May 01, 2005
Estimated Completion Date:
June 30, 2008

Study Description

The purpose of this study is to compare the efficacy and safety of haloperidol and olanzapine in the control of chronic nausea with advanced cancer patients who have failed first line antiemetic therapy.

Connect with a study center

  • Tom Baker Cancer Centre

    Calgary, Alberta T2N 4N2
    Canada

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.